Clinical outcomes after insulin initiation in patients with type 2 diabetes: 6-month data from the INSTIGATE observational study in five European countries

Current Medical Research and Opinion

Volumn 27, Issue 5, 2011, Pages 887-895

  Liebl, Andreas ^a   Jones, Stephen ^b   Benroubi, Marian ^c   Castell, Conxa ^d   Goday, Albert ^e   Aline Charles, Marie ^f,g   Smith, Helen T ^h   Nicolay, Claudia ⁱ   Simpson, Alexander ^h  

^a Centre for Diabetes and Metabolism   (Germany)

^b JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^c IASO GENERAL HOSPITAL   (Greece)

^d Generalitat de Catalunya ^*  (Spain)

^e HOSPITAL DEL MAR   (Spain)

^f CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^g UNIVERSITÉ PARIS SACLAY   (France)

^h ELI LILLY AND COMPANY   (United States)

ⁱ LILLY DEUTSCHLAND GMBH   (Germany)

Author keywords

glycaemic control; HbA1c; insulin therapy; type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; ARTICLE; BODY MASS; DISEASE DURATION; FEMALE; FRANCE; GERMANY; GLYCEMIC CONTROL; GREECE; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTCOMES RESEARCH; SPAIN; UNITED KINGDOM;

AGED; DIABETES MELLITUS, TYPE 2; EUROPE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 79954558477     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.555755     Document Type: Article

References (24)

1. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2009;32(Suppl. 1):S13-61.
2. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12. (Pubitemid 30609442)
3. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963-72. (Pubitemid 44156663)
4. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009;52:17-30.
5. The International Diabetes Federation (IDF). Global Guideline for Type 2 Diabetes. Available at: http://www.idf.org/home/index.cfm?node=1457 (Last accessed 30 October 2010).
6. Hermansen K, Mortensen LS, Hermansen ML. Combining insulins with oral antidiabetic agents: effect on hyperglycemic control, markers of cardiovascular risk and disease. Vasc Health Risk Manag 2008;4:561-74. (Pubitemid 352037916)
7. Koro CE, Bowlin SJ, Bourgeois N, et al. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004;27:17-20. (Pubitemid 38196703)
8. Bainbridge KE, Cowie CC, Rust KF, et al. Mitigating case mix factors by choice of glycaemic control performance measure threshold. Diabetes Care 2008;31:1754-60.
9. Swinnen SG, Holleman F, DeVries JH. The interpretation of glucose clamp studies of long-acting insulin analogues: from physiology to marketing and back. Diabetologia 2008;51:1790-5.
10. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analogue glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000;49:2142-8.
11. Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007; 357:1716-30. (Pubitemid 350005153)
12. Jones S, Benroubi M, Castell C, et al. Characteristics of patients with type 2 diabetes mellitus initiating insulin therapy: baseline data from the INSTIGATE study. Curr Med Res Opin 2009;25:691-700.
13. German Diabetes Association. Guidelines for diabetes care. Available at: http://www.diabetes.versorgungsleitlinien.de/ (Last accessed 30 October 2010).
14. Henderson JN, Allen KV, Deary LJ, et al. Hypoglycaemia in insulin-treated type 2 diabetes: frequency, symptoms and impaired awareness. Diabet Med 2003;20:1016-21. (Pubitemid 41701483)
15. Gao Y, Guo XH, Vaz JA; the PRESENT Study Group. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: Chinese PRESENT study. Diab Obes Metab 2009;11:33-40.
16. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
17. Holman RR, Paul SK, Bethel MA, et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89.
18. Liebl A, Prager R, Binz K, et al. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER study: a randomized controlled trial. Diab Obes Metab 2009;11:45-52.
19. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Eng J Med 2008;358:2545-59.
20. Riddle MC, Ambrosius WT, Brillon DJ, et al. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 2010;33:983-90.
21. Leiter LA, Ceriello A, Davidson JA, et al. Postprandial glucose regulation: new data and new implications. Clin Ther 2005;27(Suppl. B):S42-56.
22. Peter R, Okoseime OE, Rees A, et al. Postprandial glucose - a potential therapeutic target to reduce cardiovascular mortality. Curr Vasc Pharmacol 2009;7:68-74.
23. Monnier L, Colette C, Dunseath GJ, et al. The loss of postprandial glycaemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 2007;30:263-9. (Pubitemid 46198328)
24. Jenkins N, Hallowell N, Farmer AJ, et al. Initiating insulin as part of the treating to target in type 2 diabetes (4-T) trial: an interview study of patients' and health professionals' experiences. Diabetes Care 2010;33:2178-80